NR3C2 and hypertensive disorder: It has been hypothesized that in the SHR, elevated hypothalamic magnocellular expression of the mineralocorticoid receptor (MR) drives AVP release to contribute to the maintenance of hypertension—a theory supported by MR antagonism normalizing blood pressure in the SHR phenotype [29].